Antibody Discovery Services Market to Reach $3.54 Billion by 2030, Driven by AI Integration and Next-Gen Biologics Innovation

Posted on
by

Antibody Discovery Services Market to Reach $3.54 Billion by 2030, Driven by AI Integration and Next-Gen Biologics Innovation
Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) – Global Forecast to 2030

According to MarketsandMarkets™, the global Antibody Discovery Services Market is poised for significant expansion, projected to grow from $1.90 billion in 2025 to $3.54 billion by 2030, registering a robust CAGR of 13.3%. This growth reflects a fundamental shift in biologics R&D, where speed, precision, and scalability are becoming critical competitive differentiators.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182887795

Browse

  • 410 Market Data Tables
  • 60 Figures
  • 379 Pages and in-depth TOC on “ Antibody Discovery Services Market – Global Forecast to 2030 ”.

 

As pharmaceutical and biotechnology companies intensify their focus on next-generation therapeutics, including bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs), demand for specialized discovery services continues to accelerate. At the same time, the integration of AI-driven platforms and end-to-end service models is transforming traditional discovery workflows—enhancing efficiency, reducing timelines, and enabling more predictable outcomes.

However, despite strong momentum, high costs and technical complexity associated with biologics discovery remain key barriers, particularly for emerging biotech firms seeking market entry or expansion.

Engineering & Optimization Services Emerge as Strategic Growth Engine

Among service categories, antibody engineering & optimization is expected to register the fastest growth through 2030. This segment plays a pivotal role in refining antibody candidates for clinical success, with capabilities spanning:

  • Affinity maturation and humanization

  • Fc engineering and stability enhancement

  • Structure-guided design and computational modeling

As the industry shifts toward high-performance biologics, these services are becoming indispensable for improving efficacy, safety, and manufacturability—ultimately increasing the probability of regulatory approval and commercial success.

Monoclonal Antibodies Maintain Market Leadership

Monoclonal antibodies (mAbs) continue to dominate the molecule segment, accounting for the largest market share in 2024. Their target specificity, clinical reliability, and broad therapeutic applicability across oncology, autoimmune diseases, and infectious conditions position them at the core of global drug development pipelines.

The sustained success of mAbs has reinforced their role as a cornerstone of biologics innovation, with service providers scaling capabilities to meet growing demand for high-quality, development-ready candidates.

Asia Pacific Emerges as High-Growth Innovation Hub

The Asia Pacific region is expected to deliver the highest CAGR over the forecast period, driven by:

  • Rapid expansion of biotech and pharmaceutical ecosystems

  • Increasing R&D investments and government funding

  • Growing availability of skilled scientific talent

  • Cost advantages in research and clinical development

Countries such as China, India, South Korea, and Japan are becoming strategic outsourcing destinations, attracting global players seeking efficiency and scalability in antibody discovery programs.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=182887795

Competitive Landscape: Strategic Partnerships and Platform Innovation

The market features a dynamic mix of global CROs, biotech innovators, and specialized service providers. Key players include: Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), Sino Biological, Inc. (China), Shanghai ChemPartner (China), Biocytogen (China), Samsung Biologics (South Korea), Fusion Antibodies (UK), Twist Bioscience (US), Curia Global, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), GenScript (US), Creative Biolabs (US), Viva Biotech (China), Harbour BioMed (China), ImmunoPrecise Antibodies Ltd. (Canada), and Aragen Life Sciences Ltd. (India) among others.

These organizations are actively investing in automation, AI integration, and strategic collaborations to strengthen their service portfolios and capture emerging opportunities in biologics development.

Executive Takeaway

For decision-makers, the antibody discovery services market represents a high-growth, innovation-driven opportunity. Companies that prioritize advanced engineering capabilities, digital integration, and global delivery models will be best positioned to lead in the next wave of biologics innovation.

Related Reports:

Monoclonal Antibody Therapeutics Market – Global Forecast to 2029

Hematology Analyzers and Reagents Market – Global Forecast to 2029

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/antibody-discovery-market-182887795.html